If Pharmac funded breast cancer drugs Ibrance and Kadcyla , they'd have to stop providing another drug
If Pharmac funded breast cancer drugs Ibrance and Kadcyla , they'd have to stop providing another drug
26 March 2019
Women have been asking Parliament for funding.
But Pharmac has defended its decision, saying other drugs are cheaper and have more certainty.
CEO Sarah Fitt says New Zealand has a capped budget.
She says Pharmac's nearly one-billion taxpayer dollars needs to be spent wisely.
Fitt says Pharmac has to look at all medicine applications and make evidence-based, robust decisions.
© 2024 Newstalk ZB, NZCity